Compugen

A clinical-stage cancer immunotherapy company utilizing an AI-powered predictive computational discovery platform to identify novel drug targets and develop cancer immunotherapies.

Health Tech & Life Sciences
public
Public Holon, Israel Founded 1993
Last updated 2026-11-09
Total raised
$804.0M
Last: Public Offering 2021-11
Stage
Public
Founded
1993
Headcount
75
HQ
Holon, Israel
Sector
Health Tech & Life Sciences

About

Compugen is a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery. The company has been at the forefront of decoding cancer biology with its AI-powered predictive computational discovery platform, Unigen™. Unigen™ combines deep scientific knowledge, AI/ML predictive algorithms, and a cloud-based, technology-agnostic platform integrating various biological data. The outcomes from preclinical and clinical trials enrich its proprietary knowledgebase to discover additional novel drug targets and further understand complex biology. To date, Unigen™ has yielded multiple novel immuno-oncology drug targets, potential first or best-in-class clinical stage immuno-oncology programs, validating partnerships with multiple pharmaceutical companies, and undisclosed programs in its early-stage pipeline.

Funding history · 13 rounds · $804.0M total

13 events/rounds · $804.0M Total Funding: $35.0M in Private Equity, $769.0M in Public Equity
Jan 2023
Public Offering $50.0M EDGAR filing SEC-EDGAR 424B5
Mar 2020
Public Offering $75.0M EDGAR filing SEC-EDGAR 424B5
Jun 2018
Public Offering $21.0M EDGAR filing SEC-EDGAR 424B5
Oct 2016
Public Offering $200.0M EDGAR filing SEC-EDGAR 424B2
Sep 2014
Public Offering $200.0M EDGAR filing SEC-EDGAR 424B2
Feb 2014
Public Offering $63.0M EDGAR filing SEC-EDGAR 424B5
Jan 2013
Public Offering $100.0M EDGAR filing SEC-EDGAR 424B2
Jan 2011
Public Offering $40.0M EDGAR filing SEC-EDGAR 424B3
Oct 2009
Public Offering $20.0M EDGAR filing SEC-EDGAR 424B5
Jan 2002
Public Offering Undisclosed cgen.com
Aug 2000
Public Offering Undisclosed prior (startupim db)
Jul 2000
B Round $35.0M globes.co.il
Feb 1993

Offices

Holon, Israel · HQ / main office

Q&A

What is Compugen's primary focus?
Compugen is a clinical-stage cancer immunotherapy company that uses an AI-powered predictive computational discovery platform, Unigen™, to identify novel drug targets and develop cancer immunotherapies.
When was Compugen founded and where is it headquartered?
Compugen was founded in February 1993 and is headquartered in Holon, Israel.
What is Compugen's current employee count?
Compugen has 51-200 employees.
How much funding has Compugen raised in total?
Compugen has raised a total of $804,000,011.15 USD.
When was Compugen's most recent public offering?
Compugen had a public offering in January 2023, raising $50,000,000.
Which investors participated in Compugen's B Round funding?
Compugen's B Round in July 2000, which raised $35,000,000, included Apax and Yozma Group Korea among its lead investors.
Who are the founders of Compugen?
The founders of Compugen are Eli Mintz, Simchon Faigler, and Amir Natan.
What is the name of Compugen's AI-powered discovery platform?
Compugen's AI-powered predictive computational discovery platform is called Unigen™.

Team · 18

Eli Mintz
Founder · founders
Simchon Faigler
Founder · founders
Amir Natan
Founder · founders
Eran Ophir
President & CEO
David Silberman
Chief Financial Officer
Michelle Mahler
Chief Medical Officer
Pierre Ferre
Chief Operating Officer
Sharon Kredo-Russo
Senior Vice President, Research & Discovery
Zurit Levine
Senior Vice President, Business Development
Dorit Amitay
Vice President, Human Resources
Eran Ben Dor
General Counsel and Corporate Secretary
Anat Cohen-Dayag
Executive Chair of the Board of Directors
Michele Holcomb
Board of Directors
Eran Perry
Board of Directors
Gilead Halevy
Board of Directors
Mathias Hukkelhoven
Board of Directors
Kinneret Livnat Savitzky
Board of Directors
Sandy Zweifach
Board of Directors

Sectors & technology

Primary sector
Health Tech & Life Sciences
Technologies
Target customers

Highlights

Patents

Tags

immunologyoncologybiotechnologybioinformaticsantibodiesdrug-discoveryproteinspharmaceuticalsimmunotherapycancer-therapyautoimmune-diseasespatientspharma-companiescancerai-mlcomputational-biology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitecgen.com/
LinkedInlinkedin.com/company/753626
X / Twittertwitter.com/CompugenLtd
Wikipediaen.wikipedia.org/wiki/Compugen_Ltd.
Wikidatawikidata.org/wiki/Q5157220

Identifiers & details

Legal nameCompugen Ltd.
Founded1993-2
Employees (exact)75
Wikidata QIDQ5157220

Radar intelligence

Open jobs — comeet

Total open2
Remote0
By departmentDrug Discovery and Validation (1), Immuno-Oncology Research (1)
By locationIsrael (2)
TitleLocationDepartment
Senior Scientist, Antibody Engineering & DiscoveryIsraelDrug Discovery and Validation
Research Lab TechnicianIsraelImmuno-Oncology Research

Patents

EPO156

Publications (Crossref)

Works10

Web history (Wayback)

Domaincgen.com

Wikidata

QIDQ5157220

Certificate / subdomain footprint

Subdomains20

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)511779639
Statusפעילה
Corp typeישראלית חברה ציבורית
Incorporated1993-02-10
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report1998
Active charges / liens0
Registry events0
Registered addressהרוקמים 26 חולון